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Purpose: To identify the molecular defect in the  UbiA  prenyltransferase  domain    containing     1  (UBIAD1)    gene    in     a
four-generation Chinese family with Schnyder corneal dystrophy (SCD).
Methods: A four-generation Chinese family with SCD and 50 unrelated normal individuals as controls were enrolled in.
The complete ophthalmic examination was performed and blood samples were taken for subsequent genetic analysis.
Mutation screening of UBIAD1 was performed by polymerase chain reaction (PCR) based DNA sequencing.
Results: The missense mutation N102S in UBIAD1 was identified in this pedigree from the mainland of China for the
first time. The molecular defect cosegregates with the affected individuals, whereas not found in unaffected family
members or normal controls.
Conclusions: The nonsynonymous mutation, N102S, in UBIAD1 detected in this family confirms that it is a mutation hot
spot not only in Caucasian but also in Chinese. This finding adds support to the proposal that N102S has been independently
mutated and argues against the likelihood of a founder effect.
Schnyder corneal dystrophy (SCD; OMIM 121800) is a
rare autosomal dominant disease characterized by bilateral
and usually symmetric cholesterol and lipid deposits in the
corneal  stroma  with  or  without  crystals.  SCD  results  in
progressive  corneal  opacification,  loss  of  visual  acuity
(especially  photopic  vision  [1]),  and  eventually  corneal
sensation  or  glare.  The  clinical  manifestation  of  this
dystrophy, while variant, is most commonly in an axially
distributed, annular, or discoid pattern. The appearance of the
cornea can be predicted based on age. Although SCD has also
been known as Schnyder crystalline corneal dystrophy, only
54% of patients have corneal crystals [1]; the nomenclature
itself confounded the ability to make an accurate diagnosis.
Recently, the International Committee for the Classification
of Corneal Dystrophies (IC3D) [2] renamed the dystrophy
Schnyder  corneal  dystrophy  to  clarify  that  crystalline
deposition was not integral to the diagnosis. Other systemic
findings associated with SCD are hypercholesterolemia and
genu valgum, which are thought to be independent traits and
are found in approximately 66% [3-5] and 4% [1] of affected
patients, respectively.
In the past decade, significant advances have been made
in determining the genetic basis of SCD. Shearman et al. [6]
first localized SCD to chromosome 1p36 through the linkage
analysis in two large Swedish-Finnish families. In 2007, Orr
et al. [7] and Weiss et al. [8] independently verified that the
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mutational UbiA prenyltransferase domain containing 1 gene
(UBIAD1) caused SCD. Thus, it is generally postulated that
the onset of SCD is associated with mutations in UBIAD1
caused by base substitution. To date, 22 different mutations
(only in exons 1 and 2) have been reported: A97T [9], G98S
[10], Y174C [11], N102S [7,8,12,13], D112G [7], D112N
[9], D118G [13], R119G [7,12], L121V [12,13], L121F [14],
V122E [9], V122G [9], S171P [13,15], T175I [7,13], G177R
[8,13], K181R [11], G186R [13], L188H [9], N232S [7],
N233H [11], D236E [13], and D240N [16]. Studies of the
genetic basis of SCD demonstrated that all mutations in the
UBIAD1  gene  were  missense  mutations,  with  N102S
postulated to be a hot spot in Caucasians because it was the
most frequent mutation [13]. SCD results from one of the
numerous mutations in UBIAD1 [7,8]. To our knowledge, the
present study contains the first description of the mutation
N102S in the Han Chinese in mainland China.
METHODS
Patients  and  controls:  This  study  was  approved  by  the
Institutional  Review  Board  of  Harbin  Medical  University
(Harbin, China), and informed consent was obtained from
each participant before participation. All subjects underwent
a  complete  eye  examination,  including  uncorrected  visual
acuity  (UCVA),  best-corrected  visual  acuity  (BCVA),
pupillary  reaction,  intraocular  pressure,  motility,  slit-lamp
examination,  corneal  sensitivity  testing,  and  fundus
examination. Corneal sensation was tested by lightly touching
the cornea with a wisp of cotton from a cotton swab. We
studied a four-generation Chinese family from northeastern
mainland China with SCD (Figure 1); the family’s ethnic
background was not Caucasian. Three patients, ten unaffected
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2685family members, and fifty healthy unrelated normal controls
were recruited in this research. In addition, each subject with
SCD underwent laboratory examinations including routine
blood tests, biochemical examination of the blood, physical
examination, and radiography of the knee joints.
Genetic  Analysis:  Venipuncture  was  performed  for  DNA
collection, and peripheral blood (3 ml) was drawn from each
subject. Genomic DNA was isolated from the peripheral blood
leukocytes using the TIANamp Blood DNA Kit (Tiangen
Biotech  Co.  Ltd,  Beijing,  China),  following  the
manufacturer’s instructions. Exons 1 and 2 of UBIAD1 were
amplified by polymerase chain reaction (PCR) using a 50-ml
reaction volume that contained 10× PCR buffer, 0.2 mM of
each deoxyribonucleotide triphosphate, 2 μl of 1 mM of each
primer, 0.5 units of Taq polymerase (Takara Biotechnology
Co. Ltd, Dalian, China), and 10–200 ng of genomic DNA.
Primers for the two coding exons of UBIAD1 were UBIAD1:
1F-CTC GTG GGG TGT AAG ACC CAC TT, 1R-GCG GCT
TAA ATT AGA AAG CCA CCT; 2F-AGT GCC CAC CTG
CAC AGT CTA AG, 2R-CAA ACT GGG CAG CTC CTT
TAC  AA  [12].  The  iCycler  Thermal  Cycler  (Bio-Rad,
Hercules, CA) was used for the thermocycling procedure. The
protocol  for  amplification  reactions  was  as  follows:
denaturation at 95 °C for 5 min, then followed by 35 cycles at
94 °C for 30 s, 63 °C to 65 °C for 30 s, 72 °C for 40 s, and the
terminal extension step at 72 °C for 8 min. The annealing
temperatures are 63 °C for exon 1 and 65 °C for exon 2. 2%
agarose  gel  was  used  to  detect  PCR  products,  and
subsequently the PCR products were purified with a TIANgel
Midi Purification Kit (Tiangen Biotech Co. Ltd). For direct
sequencing via an ABI BigDye Terminator Cycle Sequencing
kit v3.1 (ABI Applied Biosystems, Foster City, CA), the PCR
products were sequenced by an ABI 3100 Genetic Analyzer
(Applied Biosystems). Nucleotide sequences of PCR products
were  manually  compared  with  gene  annotation  from
GeneBank (NM_013319.2).
RESULTS
Clinical findings: The proband (Figure 1) was a 57-year-old
male who was referred to our center due to his complaint that
he had been “seeing things hazily” for two decades. UCVA
was 20/40 OD, 20/200 OS, and BCVA was 20/30 OD, 20/80
OS. Slit-lamp examination revealed central and paracentral
subepithelial crystalline deposits, central and midperipheral
haze, and arcus lipoides (Figure 2). Corneal sensation was
reduced in the right eye and normal in the left eye. Pupillary
reaction, intraocular pressure, and motility were normal, yet
the fundus of both eyes could not be clearly observed. Knee
valgus was not found through knee examination. The blood
biochemical examination showed elevated levels of serum
total cholesterol and low levels of calcium. He had a history
of ocular contusion injuries without treatment 25 years ago,
and no history of coronary heart disease or cerebrovascular
disease. The proband’s 34-year-old daughter (Patient III:1)
had good vision (20/15 OD and 20/20 OS); nevertheless, slit-
lamp examination demonstrated bilateral central discoid haze,
midperipheral clouding, and peripheral arcus lipoides without
crystals  (Figure  3).  Pupillary  reaction,  motility,  corneal
sensation, intraocular pressure, fundus examination, and knee
examination were all normal. The only abnormal laboratory
reading  was  a  slight  decrease  in  fasting  plasma  glucose
recorded  during  biochemical  examination  of  the  blood.
Patient IV: 1 (Figure 1) was an 11-year-old girl with good
UCVA:  20/20  OD  and  20/15  OS.  Slit-lamp  examination
revealed an almost complete circle of subtle subepithelial
crystal deposits that appeared to be asymmetric and denser in
her left eye (Figure 4). The results for her other tests were
normal except for mildly elevated serum total cholesterol and
fasting  plasma  glucose.  She  had  a  history  of  suppurative
encephalitis at two months of age.
Mutation analysis: A missense mutation on exon1, c.305A>G
(p.Asn102Ser), was identified in the heterozygous state in the
proband and affected individuals in whom UBIAD1 genetic
Figure 1. Pedigree of the proband’s family with Schnyder corneal dystrophy. Black symbols, gray symbols, and unfilled symbols represent
individuals of affected members, indeterminate phenotype, and unaffected members, respectively. Question marks indicate individuals of
unknown affected status, and arrow indicates the proband. Asterisks indicate individuals in whom DNA analysis were performed. Deceased
family member was denoted by slash.
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2686screening was performed (Figure 5). The N102S mutation was
shared by the affected members (II:1,III:1,IV:1), and absent
in  unaffected  members  and  in  the  50  unrelated  normal
controls. The proband’s brother (II:5) of an undetermined
affected status has been demonstrated to be an unaffected
member because the N102S mutation was not identified.
DISCUSSION
SCD is a rare corneal dystrophy; there are rare sporadic cases.
Although most SCD pedigrees have had European ancestry
with Swedish or Finnish origins [17], the dystrophy has also
been reported in the Asian population [7,10,11,18]. SCD has
been found in Caucasian, Occidental, and African-American
populations [1]; in Asia, Chinese, Japanese, Indian, and Saudi
Arabian populations have manifested with SCD [1,10,11,14,
19]. Reports of SCD in Chinese individuals are rare, and have
appeared as single cases or as cases where only a few family
members are afflicted.
In  the  present  study,  we  identified  a  heterozygous
missense  mutation  c.305A>G  (p.Asp102Ser),  which  was
confined to the three affected individuals in the SCD pedigree
(Figures 1 and Figure 5). The mutation was not found in any
unaffected individual in the family, in 50 unrelated controls,
or  in  the  Single  Nucleotide  Polymorphism  database
(dbSNP), providing evidence to support the hypothesis that
SCD is caused by UBIAD1 mutations. The N102 is a highly
conserved gene sequence in putative gene orthologs from
other  vertebrate  and  invertebrate  genomes  (Figure  6).
Moreover, it was reported that N102S is the most frequent
mutation found in Caucasian SCD patients of either European
or unknown ethnicity [13]. Cumulatively, 12/31 (39%) of
apparently unrelated families possess this single alteration
[9]. These families are of different ethnicities described as
Figure  2.  The  proband’s  corneal
findings. Corneal photos of the proband
demonstrate  central  and  paracentral
crystalline  deposits,  central  and
midperipheral haze, and arcus lipoides
in a 57 year old male. A and B: External
photographs of OD and OS. C and D:
Slit-lamp  photograph  of  OD  and  OS,
demonstrate  subepithelial  crystalline
deposits.
Figure  3.  Corneal  findings  of  the
proband’s  daughter.  External
photographs  of  the  cornea  of  the
proband’s  daughter,  a  34  year  old
female, III:1, with central discoid haze,
midperipheral clouding, and peripheral
arcus lipoides, without crystals. A: OD
and B: OS.
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2687British, German, Czechoslovakian, Italian, Irish, Canadian,
and American with unknown ethnicity, Chinese (Taiwanese),
and Japanese [9,13]. Genetic analysis of families suggested a
putative mutational hotspot, i.e., N102S, in Caucasians. To
date, in the published literature, all Chinese pedigrees with
SCD possessing the N102S mutation are from Taiwan [13].
Our patients in the present study are Han Chinese from a
family in the northeast region of mainland China; moreover,
they  have  no  ethnic  relationship  with  Caucasians  of  any
background. Hence, the identification of a mutation of the
UBIAD1 gene in this study expands the number of ethnicities
for which the spectrum of mutation described earlier in the
Figure  4.  Corneal  findings  of  the
proband’s granddaughter. The corneas
of  an  11  year  old  female,  IV:1,  with
almost  complete  circle  of  crystalline
deposition  that  appears  to  be  not
symmetric. The crystals in left eye (B,
D) is more than that in right eye (A, C).
Figure  5.  Mutation  in  UBIAD1.
Chromatograms of the subjects whose
DNA samples were sequenced directly
showing heterozygous mutation N102S
in  exon  1.  Normal  sequence  of
UBIAD1 near codon 102 detected in a
healthy control (A, B) is showed on the
first  of  forward  and  reverse  reading,
respectively. The left ones are forward
reading, and the right ones are reverse
reading. The sequence in the proband
(C,  D)  shows  a  heterozygous  A>G
transversion (at condon 102 leads to a
change from asparagine (AAC) to serine
(AGC), which is highlighted in yellow),
which is also in other affected members:
the proband’s daughter (E, F), and the
proband’s  granddaughter  (G,  H),  but
not  in  any  unaffected  members  or
normal  controls.  The  indeterminate
phenotype member (I, J) in Figure 1 is
determined as unaffected individual due
to the chromatograms are the same with
the controls (A, B).
Molecular Vision 2011; 17:2685-2692 <http://www.molvis.org/molvis/v17/a290> © 2011 Molecular Vision
2688article is present. As a result of this discovery, a new challenge
has presented itself with regard to determining whether the
N102S  mutation  is  independent  or  the  result  of  founder
mutation [13]; Nickerson et al. [9] noted that some families
with  the  N102  mutation  may  be  distantly  related.  The
nonsynonymous mutation, N102S, in UBIAD1 detected in this
family confirms that it is a mutation hot spot not only in
Caucasians but also in Chinese populations. This finding adds
support  to  the  proposal  that  N102S  has  independently
mutated, and argues against the likelihood of a founder effect.
The  UBIAD1  causative  gene  for  SCD  is  a  highly
conserved  gene  spanning  22  kb  localized  in  chromosome
1p36.  The  locus  contains  up  to  five  exons  with  several
different  potential  transcripts.  Bioinformatics  analysis
suggests that the UBIAD1 protein is an intrinsic membrane
protein with a prenyltransferase functional domain and up to
eight  transmembrane  spanning  regions  [7].  To  date,  22
different mutations have been reported in publications, only
in exons 1 and 2; in other words, all identified mutations
occurred within the predicted prenyltransferase domain. In the
predicted two-dimensional model the locations of mutations
found  in  previous  research  showed  several  clusters  of
mutations, which were circled. These mutations were each
composed  of  an  aqueous  portion  and  two  transmembrane
helices, and described as loops 1, 2, and 3. All alterations
discovered in amino acids of UBIAD1 faced the other aqueous
compartment (i.e., on the other side of membrane). A tertiary
model showed transmembrane helices forming a substrate
binding cleft on one side of the lipid bilayer. N102S occupied
the positions where the first transmembrane helices emerged
Figure 6. The aligment of UBIAD1 putative orthologs in vertebrate
and invertebrate. The N is highly conserved in UBIAD1 proteins
from diverse species.
from  the  membrane  within  the  putative
polyprenyldiphosphate binding site, as identified by Suvarna
et al. [20] and Melzer et al. [21], in loop 1 of UBIAD1. More
recently, Nickerson et al. [9] identified that both wild-type and
the  N102S  protein  were  localized  subcellularly  to
mitochondria  by  immunohistochemistry  using  antibodies
specific for UBIAD1 protein in keratocytes. They also found
a putative second substrate of UBIAD1, naphthalin-1, 4-diol,
which  fitted  well  into  the  binding  pocket  and  docked
preferentially in the central cavity in close proximity to amino
acid,  N102.  The  3-D  model  showed  the  N102  residue,  a
spacefill  atom  with  a  docked  farnesyldiphosphate,  the
sidechain of which pointed inwards toward the center of a
speculated prenyldiphosphate binding pocket. The mutation,
N102S, had completely changed binding of the substrate, and
prenylation at position 3 was no longer possible. Thus, it is
speculated that mutated N102 residue plays a critical role in
SCD,  which  would  block  the  critical  steps  in  catalysis
suggested by UBIAD1 substrate docking models [9]. The
locations of mutation clusters are interesting; whether all of
the mutations have a similar effect and whether the function
of the mutated protein is up- or down-regulated are still not
resolved, though it has been indicated by Nickerson et al. [9]
that the activity of mutated protein appeared to be down-
regulated. Moreover, additional experiments are necessary to
explain the amino acid alternations on one side of the lipid
bilayer, and to identify the actual ligand that binds UBIAD1.
Further  researches  need  to  be  undertaken  to  determine
whether these mutations affect protein folding and/or targeted
for degradation, and whether other mutations like N102S were
localized subcellularly in the same fashion as the wild-type
proteins.
An important distinguishing feature of SCD is that it is
associated  with  a  systemic  manifestation,
hypercholesterolemia, which is found in approximately 66%
of affected patients [3-5]. Our findings in this pedigree (2 of
3 patients had hypercholesterolemia) are consistent with this
discovery. Both affected and unaffected individuals in the
family with SCD may have hyperlipoproteinemia (type IIa,
III, or IV) [2]. Serum lipid, lipoprotein, or cholesterol levels
may be normal or abnormal in the patients; this is also true for
unaffected members of the pedigree [3,18,22-24]. Affected
members of a pedigree demonstrate a higher prevalence of
hypercholesterolemia than does the general population [23].
In this Chinese SCD pedigree, the majority of family members
who were examined included patients with abnormal lipid
metabolism (Table 1). Even though many patients with SCD
have  dyslipidemia,  there  is  no  relationship  between  the
severity of the dyslipidemia and the occurrence of crystal
formation, according to overall consensus [25]. Meanwhile,
it is considered that the progress of corneal opaciﬁcation is not
associated with serum lipid levels [26,27]. In spite of the
knowledge  already  gathered,  the  pathogenesis  of  SCD  is
unclear.  SCD  is  presumed  to  be  due  to  a  localized  lipid
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2689metabolism defect in the cornea. It is postulated that one
possible reason for SCD is the overproduction of cholesterol
according to the UBIAD1 gene producing a protein with a
prenyltransferase domain, which plays a role in cholesterol
metabolism. Another possible cause is a defect in the removal
of cholesterol in view of the interaction of UBIAD1 and the
COOH-terminal portion of apolipoprotein E, which mediates
removal of cholesterol from cells [13]. Recently, Nickerson
and colleagues [9] analyzed cholesterol metabolites in patient
cell  line  extracts.  This  analysis  showed  no  significant
alteration  in  the  presence  of  mutant  protein,  indicating  a
potentially  novel  function  of  the  UBIAD1  protein  in
cholesterol biochemistry [9]. More experimental studies will
determine whether the excess cholesterol in the cornea results
from  increased  cholesterol  production  or  decreased
cholesterol removal.
The clinical findings in the patients identified in this study
are consistent with corneal appearance predicted based on age,
as previously described [28]. Patients younger than 23 years
demonstrate only a central corneal opacity with or without
central subepithelial cholesterol crystals and possess excellent
visual  acuity  and  normal  corneal  sensation  (Patient  IV:1,
Figure 4). Patients aged 23–39 years develop arcus lipoides,
and visual acuity may be diminished (Patient III: 1, Figure 3).
In patients older than 39 years, a mid-peripheral, panstromal
corneal haze appears that fills in the areas between the central
opacity and the peripheral arcus (which could be seen without
a slit lamp), and an objective loss of visual acuity and reduced
corneal  sensation  (the  proband,  Figure  2).  The  decreased
corneal sensation in the proband could be explained by what
has  been  found  in  confocal  microscopy  examination:
intracellular  and  extracellular  highly  reflective  deposits
leading  to  eventual  disruption  of  the  basal  epithelial/
subepithelial nerve plexus [2].
There was no genotype–phenotype correlation for the
majority  of  mutations;  phenotypic  variation  was  present
within families. We found affected individuals shared the
same  N102S  mutation,  but  had  very  different  corneal
appearance  (Figure  2,  Figure  3,  and  Figure  4).  Affected
individuals  from  different  families  possessed  different
mutations,  but  had  virtually  identical  corneal  ﬁndings,  as
described in the literature. It is presumed that modulating
inﬂuences such as environmental effects lead to the observed
phenotypic heterogeneity, and that the interaction of multiple
genes resulted in a speciﬁc phenotype [13].
Interestingly,  we  identified  7  of  10  family  members
(70%) in whom blood biochemical examinations (Table 1)
showed decreased serum calcium levels, while levels of serum
phosphorus  were  normal.  Serum  calcium  and  phosphorus
levels were also normal in the spouse of the proband. As yet,
no  relationship  between  SCD  or  UBIAD1  and  calcium
metabolism has been described in the literature; hence there
is no inconsistency between our results and other published
work. By consulting a broad range of articles, we speculate
that UBIAD1 may impact the serum calcium level through an
effect on the vitamin K-dependent enzyme and its derivatives.
A  recent  study  found  that  UBIAD1  was  a  human
Menaquinone-4 (MK-4, i.e., vitamin K2) biosynthetic enzyme
[29]. In fact the activity of vitamin K encompasses many kinds
of  physiologic  processes,  including  blood  coagulation,
regulation of tissue calcium content [30], and gene activity
[31]. Vitamin K also has effects on growth regulation [32],
anti-inflammation  [33],  anti-canceration  [34],  and
antioxidation [35]. Coincidentally, the location for vitamin K
recycling—a very crucial process for its biologic action [30]
—and the location of UBIAD1 protein (of osteoblast cells)
[29]  are  both  in  the  endoplasmic  reticulum  membrane.
Moreover, it was demonstrated that vitamin K is a cofactor in
TABLE 1. BIOCHEMICAL FINDINGS.
Individual Age TC TG HDL-C LDL-C Calcium Glucose Apo B
II:1 57 ↑ N N N ↓ N /
II:2 58 N ↑ N N N N /
II:4 56 N N ↑ N ↓ N ↓
II:5 54 ↑ N ↑ N N ↑ N
II:8 51 ↑ N ↑ ↑ ↓ ↑ N
III:1 34 N N N N N ↓ /
III:3 24 ↑ ↑ N ↑ ↓ N /
III:4 30 N N ↑ N ↓ N N
III:7 26 N N ↑ N ↓ N ↓
III:10 26 N N ↑ N ↓ N ↓
IV:1 11 ↑ N N N N ↑ /
        Arrow upward indicates which comparing to normal is higher, conversely arrow downward is used, and N is shot for normal.
        The sprit indicates that there is no result obtained. TC=total cholesterol; TG=triglyceride; HDL-C=high density lipoprotein
        cholesterol; LDL-C=low density lipoprotein cholesterol; Apo B=apolipoprotein B.
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2690bone metabolism [36,37]. Vitamin K has activity in the post-
translational modification of vitamin K-dependent proteins,
which involves the conversion of glutamic acid residues to
gamma-carboxyglutamic acid residues, enables the enzyme to
carboxylate selected proteins in targeted glutamate groups. In
the process, vitamin K functions as a cofactor with gamma-
glutamyl carboxylase. In addition, vitamin K2 has the most
potent gamma-carboxylation activity [38]. Some vitamin K-
dependent proteins, such as calbindin and osteocalcin, are also
calcium-binding  proteins  that  play  a  role  in  calcium
homeostasis  and  in  facilitating  bone  mineralization  [39].
Furthermore, some recent studies reveal that osteocalcin is
involved in metabolism in both bone metabolism and energy
metabolism, including glucose and lipid metabolism.
Osteocalcin is expressed in many tissues, secreted from
osteoblasts,  and  produced  and  regulated  by  1,25-
dihydroxyvitamin D, glucocorticoids, estrogens, and retinoic
acid [39]. Osteocalcin exists in two forms: carboxylated (this
form accounts for most osteocalcin) and undercarboxylated.
Carboxylated osteocalcin is essential for bone mineralization,
which binds calcium strongly and consolidates calcification
of the hydroxyapatite crystal lattice in bone; some  osteocalcin
is undercarboxylated and is located in the circulation, where
it  involves  in  the  regulation  process  such  as  glucose
metabolism,  lipid  metabolism,  and  insulin  secretion  and
sensitivity. Other research found that serum osteocalcin was
associated with metabolism of lipids, including triglycerides,
cholesterol, and high-density-lipid cholesterol (HDL-C) [40].
Table 1 shows the number of members of the current pedigree
with high HDL-C levels. Serum calcium is lower in patients
after  obesity  surgeries,  with  the  serum  osteocalcin  level
changing while the phosphorus level remains normal [41].
Interestingly,  both  the  osteocalcin  gene  and  UBIAD1  are
located  on  chromosome  1.  There  may  be  an  as-yet
incompletely  characterized,  complicated  relationship
between osteocalcin and UBIAD1 in SCD.
In summary, it is possible that some unknown has not
been identified in SCD, and in the function of UBIAD1 to
explain serum calcium in low levels. More studies are needed
to  determine  whether  serum  calcium  or  osteocalcin  is
associated with SCD or with UBIAD1.
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